Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04040504 |
| Other study ID # |
REB19-0983 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
December 3, 2019 |
| Est. completion date |
March 31, 2022 |
Study information
| Verified date |
June 2022 |
| Source |
University of Calgary |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
1. Background & Rationale
Over 650,000 endoscopic retrograde cholangio-pancreatography (ERCP) procedures are
performed annually in the United States alone. ERCP is universally performed using a
highly specialized type of flexible endoscope called a duodenoscope. Though critical for
the successful completion of ERCP, the design of duodenoscopes makes them among the most
complicated medical devices that require routine disinfection and reprocessing. In
recent years, several ERCP-related infectious outbreaks have occurred.
Thus, it is clear that novel strategies need to be developed in order to prevent future
ERCP-related outbreaks. Specialized duodenoscopes with disposable caps have been
developed, and these represent a promising new modality with the potential to
drastically reduce the rates of duodenoscope-related infection.
2. Research Questions & Objectives
There are two co-primary outcomes in this study; the first is to determine the clinical
efficacy of a novel duodenoscope with a disposable elevator cap (DEC) system compared
with a duodenoscope with a traditional design. The second co-primary objective is to
determine the rate of persistent pathogenic contamination of the novel duodenoscope
following standardized disinfection and reprocessing protocols compared with a
traditional duodenoscope.
3. Methods
This is a prospective, consecutive, randomized controlled study. The intervention arm will
comprise use of the ED34-i10T2 duodenoscope with DEC, along with any required standard ERCP
accessories, whereas the control arm will comprise use of the ED34-i10T duodenoscope with any
required ERCP accessories. All procedures will be performed by expert endoscopists with
adequate training, or by advanced endoscopy trainees under direct supervision.
Collected data will include primary endpoints listed above, in addition to patient
demographics, endoscopist and trainee data, sedation used, procedural details, and
peri-procedural data. Data will be collected at index procedure and at 30-day follow-up. All
data will be recorded on REDCap.
Description:
There are two co-primary objectives of this study; the first is to determine the clinical
efficacy of a novel duodenoscope with a disposable elevator cap (DECTM) system compared with
a duodenoscope with a traditional design. The second is to determine the rate of persistent
pathogenic contamination of the novel duodenoscope following standardized disinfection and
reprocessing protocols, compared with a traditional duodenoscope.
This is a prospective, consecutive, randomized controlled study which will assess 1) the
clinical efficacy of DEC versus standard duodenoscopes and 2) the persistent bacterial
contamination rate of DEC versus standard duodenoscopes. The intervention arm will comprise
use of the ED34-i10T2 duodenoscope with DEC, along with any required standard ERCP
accessories, whereas the control arm will comprise use of the ED34-i10T duodenoscope with any
required ERCP accessories. The study will take place at a single high-volume tertiary ERCP
referral center in Calgary, Alberta, Canada, where over 1,500 ERCPs are performed annually.
All procedures will be performed by trained endoscopists having each performed over 1,000
ERCPs or by advanced therapeutic endoscopy trainees under direct supervision of the expert
endoscopists.
All consecutive patients at the study center who meet the eligibility criteria below will be
invited for participation in the study. Patients who sign the informed consent form will be
considered enrolled. In cases where it is determined that the patient failed to meet the
eligibility criteria after the patient has agreed to participate in the study and/or has
signed the informed consent, the study personnel will complete screening forms as well as
indicate the specific inclusion/exclusion criterion that was not met. Such a patient will be
considered a screen failure and will not count towards the final analyses.
Patients fulfilling the inclusion/exclusion criteria above will be randomized following
consent in a 1:1 ratio. Permuted block randomization will be utilized in blocks of 8
patients. Allocation will be to one of two groups: 1) ERCP using ED34-i10T2 duodenoscope with
DEC or 2) ERCP using a conventional duodenoscope (ED34-i10T). Confidential random number
allocation will be accessed via a secure internet software. The study investigators, outcome
adjudicators and patients will be blinded to allocation. The endoscopist will not be blinded.
In cases where additional or alternate duodenoscope(s) is/are required to achieve the desired
goal of the ERCP procedure, the choice(s) of device(s) will be left to the discretion of the
endoscopist, regardless of the study arm to which the patient has been allocated.
The investigators have previously designed and implemented the Calgary Registry for Advanced
and Therapeutic Endoscopy (CReATE, University of Calgary Conjoint Health Research Ethics
Board 18-0410). CReATE is a high-fidelity prospective database that seeks to answer questions
in ERCP outcomes research. As such, over 400 data fields are collected in real-time for each
ERCP procedure, including detailed patient-, endoscopist- and procedure-based variables.
Therefore, CReATE serves as the ideal data collection platform for this prospective
randomized trial.
Data are inputted by a full-time research assistant, and stored and managed on a secure web
application specializing in healthcare database implementation and maintenance, REDCap.19
This web portal allows for facile access to secure data. The web portal is secured by the
latest security technology. Study participants will be identifiable on the secure platform
for purposes of patient contact, follow-up and potential withdrawal. For the purposes of this
randomized study, an additional tab will be created in the electronic interface that will
allow for entry of the arm to which the patient has been randomized. Whenever data are
exported for analysis, they will be de-identified and assigned unique study codes only. The
primary investigator will be the custodian of the identifiable electronic data, which will be
stored only on a secure server accessible only via combination of password protection and
temporary electronic fob.
Consecutive patients undergoing ERCP will be flagged as potentially eligible for study
participation. On the day of the procedure, the patient will be approached by a research
assistant (RA), who will explain the study, confirm eligibility, and answer any potential
questions. If the patient agrees to participate, the relevant informed consent form is signed
and witnessed. If the patient decides not to participate, the ERCP proceeds as per the usual
standard of care, with or without the use of DEC as per the endoscopist's discretion (and the
sequence that follows does not apply).
1. The RA collects any relevant patient-related and pre-procedural data through combination
of direct patient interview and review of the medical records.
2. The patient is randomized to one of the two study arms.
3. The patient enters the endoscopy/fluoroscopy room and the procedure commences.
4. During the ERCP procedure, relevant peri-procedural data are recorded by the RA by
direct observation, and/or, if necessary, in consultation with the procedural
physician(s) and/or nurse(s).
5. After the procedure is complete, the patient is moved to the recovery room for
observation. Depending on their disposition and the course of the procedure, observation
times and protocols differ. During this stage, the RA collects any relevant
post-procedural data, and any missing pre- or peri-procedural data.
6. Any peri- or immediate post-procedural adverse event(s) is/are recorded.
7. The patient is examined by the endoscopist prior to discharge and provided with written
post-procedure information, including a phone number to call in the event of any issues.
8. The RA meets with the patient prior to their discharge from the unit to answer any final
potential questions.
After the ERCP is complete, the in-room nursing team will carry out standardized
post-endoscopy manual cleaning and disinfection of the DEC or traditional duodenoscope. In
cases where the DEC was used, the cap will be disposed of. These processes will be timed by
the research assistant. Following this, the scope will be portered to the automated
reprocessing room for disinfection and reprocessing, which will also be timed.
After reprocessing, staff will then observe the following sequence to determine whether there
is any persistent bacterial contamination despite standardized disinfection and reprocessing.
These samples will then be shipped for microbiologic analysis. The protocol for duodenoscope
sampling that will be utilized for this study is adapted from the Duodenoscope Surveillance
Sampling and Culturing Protocols, which were developed jointly by the Department of Health
and Human Services, Food and Drug Administration (FDA), Centers for Disease Control and
Prevention (CDC), and American Society for Microbiology (ASM).24 The procedure is summarized
here.
1. Two staff are needed to conduct sampling from duodenoscope channels; one person (the
sampler) will maintain aseptic handling and conduct brushing steps, while the second
person (the facilitator) will open packages and handle the unsampled portions of the
duodenoscope.
2. The staff will label the sterile sample containers with relevant information.
3. The staff will don their personal protective equipment (PPE).
4. The staff will set the duodenoscope on a sterile drape.
5. Two samples will be collected and combined. First, an instrument channel sample (from
the biopsy port to the distal scope end) will be taken.
6. Second, an elevator recess sample will be taken by flushing and brushing of the elevator
recess (in the case of the disposable cap, the distal scope tip to which the disposable
cap attaches will be sampled instead, ensuring sampling of the joint line between cap
and scope).
7. The duodenoscope will then be handled and transported back to the endoscopy unit
according to our local institutional policies.
8. Samples will be packed in appropriate biohazard containers, packaged, and transported
for microbiologic analysis. The samples will be assigned a unique study number so that
the microbiologic analysts will be blinded to the type of duodenoscope that was used for
the index procedure.
The presence of any post-reprocessing bacterial population(s) will be assessed using plating
for growth aerobic and anaerobic conditions. If after 72 hours there is no growth, the sample
will be deemed negative, and will be discarded. Positive samples will further be
characterized using serial dilutions to establish colony-forming unit (CFU) counts and
sequenced for characterization of bacterial communities using a 16S rRNA amplicon
Next-generation sequencing (NGS).
Patients will be contacted by the RA by telephone 30 days following their ERCP to assess for
any ongoing symptoms and advise of any adverse events, including unplanned emergency
department visits or inpatient admissions. The patient's medical record is also reviewed at
30 days for complete details of any unplanned emergency department visits, inpatient
admissions or prolonged admissions.
In accordance with the Declaration of Helsinki and the International Conference on
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
Good Practice Guidelines, a participant is free to withdraw from participation in the study
at any time, for any reason without prejudice to their future medical care by the physician
or the institution. The investigator(s) may also withdraw the participant at any time in the
interests of patient safety. Participants may be removed from the study if one or more of the
following events occur:
- withdrawal of consent;
- decision is made by the investigator(s) that removal from the study is in the patient's
best medical interest;
- study is stopped by ethics/regulatory authorities.
If a subject withdraws from the clinical investigation, the primary or any additional
reason(s) shall be reported. All applicable case report forms up to the point of subject
withdrawal, including an End of Study form, should be completed.
Subjects who are "lost-to-follow-up" will have three documented attempts to contact them
prior to completion of the End of Study form. If withdrawal is due to investigator's
discretion, the investigator should describe what follow-up activities the investigator shall
perform. Unless the withdrawal is due to a Serious Adverse Event (SAE), additional subject
data will not be collected after the point at which the subject has been withdrawn or
withdraws consent from the study. Data collected up to the point of withdrawal may be used by
the investigators as permitted in the Informed Consent Form (ICF).
This clinical trial will be considered complete when participants are no longer being
examined or the last participant's final 30-day follow-up check has occurred. A participant
will be considered to have completed the study if he or she has completed the index procedure
in addition to the follow-up phone assessment at the 30-day timepoint.
